These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24699471)

  • 41. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunogenicity and safety of DTaP-IPV//PRP-T combined vaccine in infants in China].
    Li YP; Li FX; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Li RC; Zhang YP; Esteban O
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):808-15. PubMed ID: 22093474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Increase in localised symptoms in 4-year-olds following revaccination with DaPT-IPV].
    David S; Vermeer-de Bondt P; van der Maas N
    Ned Tijdschr Geneeskd; 2010; 154():A980. PubMed ID: 20456777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.
    Weston WM; Klein NP
    Expert Rev Vaccines; 2008 Nov; 7(9):1309-20. PubMed ID: 18980534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.
    Macías M; Lanata CF; Zambrano B; Gil AI; Amemiya I; Mispireta M; Ecker L; Santos-Lima E
    Pediatr Infect Dis J; 2012 Aug; 31(8):e126-32. PubMed ID: 22531237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom.
    Andrews N; Stowe J; Wise L; Miller E
    Vaccine; 2010 Oct; 28(44):7215-20. PubMed ID: 20800702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of DTaP-IPV-HB vaccine on use of health services for young infants.
    Thompson LA; Irigoyen M; Matiz LA; LaRussa PS; Chen S; Chimkin F
    Pediatr Infect Dis J; 2006 Sep; 25(9):826-31. PubMed ID: 16940842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Feb; 29(10):1913-20. PubMed ID: 21219984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the reactogenicity of three different immunization schedules including diphtheria, tetanus, pertussis, Haemophilus influenza b and polio vaccine in Turkey.
    Beyazova U; Yüksel N; Aksakal FN; Camurdan AD
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):438-43. PubMed ID: 23720155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: A population-based retrospective cohort study.
    Huang K; Tao S; Zhou X; Mo J; Zhu B; Shen P; Lin H; Arena PJ; He N
    Vaccine; 2020 Apr; 38(18):3422-3428. PubMed ID: 32178909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine.
    Dutta AK; Verghese VP; Pemde HK; Mathew LG; Ortiz E
    Indian Pediatr; 2009 Nov; 46(11):975-82. PubMed ID: 19955579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: a randomized, open-label, phase 3 study.
    Bernstein HH; Noriega F;
    Vaccine; 2011 Mar; 29(11):2212-21. PubMed ID: 20609398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA; Cutland C; Jones S; Groome M; Ortiz E
    S Afr Med J; 2011 Nov; 101(12):879-83. PubMed ID: 22273029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of the safety of diphtheria, tetanus and acellular pertussis containing combination vaccines in Chengdu, 2015-2019].
    Li L; Yang RP; Cai J; Zheng JH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):958-962. PubMed ID: 32907285
    [No Abstract]   [Full Text] [Related]  

  • 60. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Group
    Hum Vaccin Immunother; 2019; 15(4):786-799. PubMed ID: 30785357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.